Global Imaging Agents Industry

• Publication date: February 2012

This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following Product Segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. Also, a six-year historic ana...

This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following Product Segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Daiichi Sankyo Company Limited, Eisai Co., Ltd, EUSA Pharma, Inc., GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Medical Imaging Industry in Europe

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. Contrast Media I-3
X-Ray Contrast Media I-3
Magnetic Resonance Imaging (MRI) Contrast Media I-4
Ultrasound Contrast Media I-4
B. Diagnostic Radiopharmaceuticals I-4


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Industry Outlook II-1
Medical Imaging Industry Under the Impact of Economic Downturn II-2
Targeted Imaging - A Game Changer in the Making? II-2
Developing Countries to Spur Growth II-3
A Quick Primer On Imaging Agents II-3
Growth Drivers II-4
Growth Inhibitors II-5
Changing Dynamics of Imaging Agents II-6
Imaging Agents: Significant Growth Ahead II-7
Rise of Non-Ionizing Imaging Techniques II-7
Fusion Imaging Modalities: Greater Clinical Benefits II-8
Radioactive Isotopes Utilized in PET & SPECT Imaging Procedures II-8
Radiopharmaceuticals-An Exotic Tool II-9
Nanomaterials Taking the Center Stage II-9
Gadolinium Coated Nanoparticles- A Promising Imaging Agent II-9
A Peek Into Pricing Dynamics II-10
A Synoptic Overview II-10
Pros & Cons II-11
Positive Factors Driving Prices II-11
Negative Factors Bearing Down on Prices II-11
Reimbursements II-11
“Under the Umbrella” II-11
Europe II-12
United States II-12

2. MARKET TRENDS & ISSUES II-13
Falling Prices Turn On the Heat II-13
X-Ray Contrast Media: Declining Sector II-13
MRI Contrast Media: Playing at Center Court II-13
Impact Wielded by Ballooning MRI Practices II-13
Ultrasound Contrast Media: A Rising Star in the Quadrant II-14
Fledging Market Battles Teething Challenges II-15
PET: A Prime Growth Driver for Radiopharmaceuticals II-15
Nuclear Medicine: A Potential Growth Avenue for
Radiopharmaceuticals II-16
Select Cardiology and Oncology Radiopharmaceuticals II-16

3. COMPETITION II-17
Market Structure II-17
Big Guns in the Emerging MRI Market II-18
Bayer Schering Pharma AG: A Pioneering Developer of MRI
Contrast Agents II-18
Competitive Scenario II-19
Table 1: Worldwide Imaging Agents Market (2009): Percentage
Breakdown of Value Sales for Leading Players- GE Healthcare,
Bracco, Covidien, Bayer Schering Pharma, and Others (includes
corresponding Graph/Chart) II-19

Table 2: X-ray Medical Contrast Media Market Worldwide
(2009): Percentage Breakdown of Sales for GE Healthcare,
Bracco, Covidien, Bayer Schering Pharma and Others (includes
corresponding Graph/Chart) II-19

Table 3: MRI Contrast Media Market Worldwide (2009):
Percentage Breakdown of Sales for Bayer Schering Pharma, GE
Healthcare, Bracco, Covidien and Others (includes
corresponding Graph/Chart) II-19

Table 4: Radiopharmaceutical Contrast Media Market Worldwide:
Percentage Share of Leading Players for 2007 - GE Healthcare,
Bristol-Myers Squibb, Mallinckrodt/ Covidien, MDS Nordion and
Others (Revenue Share) (includes corresponding Graph/Chart) II-20

4. TECHNOLOGY BREAKTHROUGHS II-21
Molecular Imaging Agents: The Outer Limits II-21
On Cards: Hyperpolarized Gases as Contrast Agents II-21
Imaging Agents Make a Welcome Impact in the Field of
Alzheimer’s Disease II-22
Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging II-22
A New Imaging Agent for Radiopharmaceutical Scans II-22
Multi-Modal Image Registration: Combating Contrast Medium
Inconsistencies II-22
Saline Flushes To Help Ensure Accurate Delivery of Contrast
Agents II-23

5. PRODUCT OVERVIEW II-24
Contrast Agents II-24
Contrast Media: How Do They Function? II-24
Where Are They Used ? II-25
Evolution of Contrast Media: A Profile II-25
Bismuth Nitrate: Beginning of Contrast Agents II-25
Imaging Agents: Significant Developments in the Last Fifty Years II-26
Schering Develops First Intravenous Contrast Agent II-26
MRI: Creating a New Era for Contrast Agents II-26
A Peek into the Finer Points of Differences Among Contrast Media II-26
Viscosity II-26
Osmolality II-27
Chemotoxicity II-27
Second Generation Non-Ionic Contrast Agents: An Introduction II-27
Choice of the Contrast Medium: A Weighty Decision II-27
Factors affecting choice of Imaging Agents II-27
Taxonomy II-28
Types of Contrast Media II-28
X-Ray Contrast Medium II-28
First Generation High Osmolar Contrast Media II-29
Second Generation Low Osmolar Contrast Media or LOCM II-29
Table 5: Comparative Analysis of Structure of Non-ionic and
ionic X-ray Contrast Media II-29
MRI Contrast Medium II-29
Role of Contrast Enhancement in MR Angiography (MRA) II-31
MRI Contrast Agents for the Liver II-31
Paramagnetic extracellular contrast agents II-31
Hepatobiliary Gadolinium Chelates II-31
Superparamagnetic Iron Oxide Particles II-31
Ultrasound Contrast Medium II-31
Ultrasonographic Contrast Media: What Are They? II-32
Ultrasound Contrast Enhancement in Cardiology II-33
Functionalities of Vascular Ultrasound Contrast Agents II-33
Diagnostic Radiopharmaceuticals II-33
Key Radioactive Isotopes used as Diagnostic
Radiopharmaceuticals II-34
A Delineate of Diagnostic Radiopharmaceuticals II-35
Diagnostic Radiopharmaceuticals: A Technical Run-Through II-35
Applications II-36

6. A SEGMENTAL REVIEW II-37
Contrast Media II-37
Popular Brands of Contrast Agents II-37
X-ray Contrast Media II-38
Market Scenario II-38
MRI Contrast Media II-39
Market Scenario II-39
Ultrasound Contrast Media II-39
Market Overview II-39
Competitive Scenario II-40
Diagnostic Radiopharmaceuticals II-40
Market Overview II-40
Immunoconjugates II-40
Market Overview II-40

7. TECHNOLOGY DYNAMICS II-42
Proprietary Technologies Making Significant In-Roads II-42
Advanced Magnetics’ Proprietary Colloidal Superparamagnetic
Particle Technology II-42
Enzon’s Single Chain Antigen-Binding Technology II-42
Immunomedics’ Antibody Technology II-42
First Generation II-42
Second Generation II-42
Third Generation II-42
NeoRx’s “Painting the Target” Technology II-43
Stage - I II-43
Stage - II II-43
Stage - III II-43
Gas Encapsulation Technology for Ultrasound Contrast Media II-43
Pharmacyclics’ Texaphyrin Technology II-44
Regulatory Bodies II-44
Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA II-44
Entry Barriers II-44
Research Driven Markets II-44
Highly Competitive Market II-45
Economies of Scale II-45
Substitutes in Agents Manufacturing II-45
New X-ray Diagnostic Agents II-45
Amide-based Macrocyclic Ligands - Potential MRI Agents II-45
Gadolinium (III) Complexes - Potential MRI Contrast Agents II-45
Metal-Containing Compounds Act As Potential Contrast Agents II-45
Therapeutic Applications II-45
Diagnostic Applications II-46
Magnetic Gels as Potential MRI Contrast Agents II-46
PFCs as Diagnostic Contrast Agents II-46

8. PRODUCT LAUNCHES II-47
GE Healthcare Receives FDA Approval for DaTscan for detecting
Dopamine Transporters II-47
Targeson Launches Targestar® P-HF II-47
GE Healthcare Announces Phase II Study Results of
Flutemetamol, the PET Imaging Agent for Brain Imaging II-47
GE Healthcare Receives FDA Approval for Cysview, An Optical
Imaging Agent for Cystoscopic Detection of Papillary Bladder
Cancer II-47
INER Develops Imaging Agents for Cerebral Blood Flow II-48
Lantheus Medical Imaging Introduces Definity Ultrasound
Contrast Imaging Agent in India II-48
Sanochemia Pharmazeutika Completes DCP Phase of MRT Imaging
Agent, to Introduce Within Major European Markets by 2011 II-48
Bayer Transfers Liver MRI Contrast Medium Resovist Injection
to I’rom Pharmaceutical II-48
GE Healthcare Re-Introduces Contrast Agent, OptisonTM II-48
Lantheus Medical Imaging Introduces ABLAVAR™ in Canada II-49
VisEn Introduces ProSense® 750 FAST and Neutrophil ElastaseTM
680 FAST II-49
Bayer Works on Development of MR Contrast Agents for Breast
Cancer Diagnosis II-49
Lantheus Medical Imaging Introduces ABLAVAR™ MRA Imaging Agent II-50
VisEn Introduces Cat B 680 FAST™ Imaging Agent II-50
VisEn Medical Introduces GastroSense 750 Fluorescence Imaging
Agent II-50
VisEn Medical Unveils VivoTag® 645 Red Fluorescent Dye II-51
VisEn Medical Launches VivoTag® 680 XL Fluorescent Dye II-51
AMAG Pharmaceuticals Unveils Superparamagnetic Iron Oxide
Nanopaticles II-51
MabCure Unveils Monoclonal Antibodies II-51
VisEn Medical Introduces ReninSense680TM FAST II-52
VisEn Medical Introduces New VivoTag® 800 and OsteoSense®
Imaging Agents II-52
VisEn Medical Introduces Annexin-Vivo 750 Imaging Agent II-52
VisEn Introduces New Fluorescence Molecular Imaging Agent,
IntegriSense™ 750 II-53

9. RECENT INDUSTRY ACTIVITY II-54
Covidien to Spin Off Pharma Business II-54
University of Montana Receives Patents for Two New Brain
Imaging Agents II-54
Eli Lilly Acquires Avid Radiopharmaceuticals II-54
GE Global Research Secures Multi-Year NIH Grant to Develop
Nerve Imaging Agent and Imaging System II-54
Agfa Healthcare Snaps Insight Agents II-55
Nordion to Divest MDS Nordion S.A. II-55
Sofie Biosciences Secures Funds for Research on Molecular PET
Imaging Agents II-55
Aposense Signs Collaboration Agreement With Roche II-55
University of Washington to Collaborate with Cardinal Health
for Advancement of Molecular Imaging II-56
ImaginAb Joins Hand with GE Imanet for Developmental Drug
Research II-56
Cancer Targeted Technology Inks Agreement with Bayer Pharma
for Cancer PET Imaging Agent II-56
Lantheus Medical Imaging Wins Global Rights for Gadofosveset
Trisodium II-57
Avid Radiopharmaceuticals Partners with Siemens PETNET
Solutions for Production of Florbetapir F 18 II-57
VisEn Expands Fluorescence Imaging Intellectual Patent
Portfolio through Acquisition of Bayer Schering’s Portfolio II-57
Cardinal Health Enters into Partnership with ProVision for
Cyclotrons II-57
Center for Diagnostic Imaging Sets up New Imaging Center II-57
ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL
Biologics II-58
Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement
for Molybdenum-99 II-58
Lantheus Medical Imaging Purchases MS-325 Related Rights from
EPIX Pharmaceuticals II-58
GE Healthcare Inks Agreement with Nycomed II-58
Photocure Secures Reimbursement Approval for Hexvix in Germany II-59
Agfa HealthCare to Acquire Insight Agents II-59
Eckert & Ziegler Disinvests FCI Contrast Media Business II-60
Guerbet Signs Distribution Agreement with Draximage for its
Nuclear Medicine Product Range II-60
ImaginAb Signs Sub Licensing Agreement for huJ591 with BZL
Biologics II-60
Lantheus Medical Imaging and NTP Radioisotopes Sign Agreement
for Molybdenum-99 II-61
Lantheus Medical Imaging Purchases MS-325 Related Rights for
Select Markets from EPIX Pharmaceuticals II-61
MDS Nordion, TRIUMF and University of British Columbia Enter
into Partnership II-61
Alseres Pharmaceuticals Signs Agreement for Special Protocol
Assessment of Altropane II-62
Pharmalucence Wins Approval from FDA for Sestamibi Kit II-62
Covidien Obtains Approval from Health Canada for Sestamibi
Injection II-62
MDS Nordion Commences Production of CardioGen-82 II-62

10. STRATEGIC CORPORATE DEVELOPMENTS IN PAST - A PERSPECTIVE BUILDER II-64
Avista Capital Partners Acquires Bristol-Myers Squibb Medical
Imaging II-64
Amerinet Awards Contract to Bayer HealthCare II-64
Bristol-Myers Squibb Medical Imaging Changes Name to Lantheus
Medical Imaging II-64
Bayer Schering Secures FDA Marketing Clearance for Primovist® II-65
Bracco-Eisai Secures Approval for Iomeron® 350 and Iomeron®
350 Syringe for Use in Dynamic Liver CT II-65
Covidien Signs Co-Marketing Deal with PETNET over Nuclear
Medicine Therapies II-66
EPIX Receives FDA Approval for Vasovist II-67
GE Global and NCI Partner to Speed-up Development of Cancer
and Heart Disease Diagnosing Nanoparticle Imaging Agents II-67
Lantheus Wins Contract from PPP II-68
Sanguine to Take over Rockland II-68
Starpharma Holdings Enters into an Agreement with Unilever II-68
GE Healthcare and Cardinal Health Enter Into a Deal II-68
Jubilant to Take Over DRAXIS II-69
MTTI and Bexion to Partner for Nanovesicle II-69
Otsuka Takes over IPP II-70
Wilex Inks Deal with IBA II-70
Eusa Pharma Takes Over Cytogen II-70
Bracco Group Acquires E-Z-EM II-70
EPIX Pharmaceuticals to Resubmit New Drug Application (NDA)
for Vasovist II-71
Bayer Schering, FutureChem Ink Licensing Deal II-71
NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive
Imaging Agent II-71
Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals II-71
Bracco Diagnostics Inks Agreement with HealthTrust Purchasing
Group II-71
Bracco Diagnostics Offers MRI Products to HealthTrust
Purchasing Group II-71
Bayer HealthCare Offers MRI Contrast Agent to HealthTrust II-72
Bayer HealthCare Extends Contract with Premier II-72
Bayer HealthCare Sets Off US Operations II-72
Tyco Healthcare Renamed to Covidien Ltd II-72
Covidien Offers Imaging Solutions to MedAssets Supply Chain
Systems II-72
Siemens, M.D. Anderson Cancer Center Set up Research Centre II-72
Bayer, Berlex Merge Operations II-73
AION Diagnostics Forays Pre-Clinical Imaging Agent Market II-73
ART Acquires Alerion Biomedical II-73
EPIX to Merge with Predix II-73
Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories II-73
Bracco Diagnostics Inks Agreement with Amerinet II-74
Vasovist receives Green Signal in Australia II-74
AION Diagnostics Develops BioSilicon TM II-74
Sonazoid Receives Import Approval II-74

11. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE
BUILDER II-75
Insight Agents to Launch Generic Contrast Media Solutions In
Europe II-75
Researchers Develop First Biocompatible MRI Contrast Agent II-75
Signalomics and Invitrogen Collaborate to Develop Nanocrystal
Reagents II-75
Schering AG Collaborates with Stanford University to Develop
Molecular Imaging Agent II-75
Schering and Avid to Develop Diagnostic Imaging Agents II-75
US National Institutes of Health Develops two PET Imaging Agents II-76

12. FOCUS ON SELECT PLAYERS II-77
AMAG Pharmaceuticals, Inc. (USA) II-77
Bayer Schering Pharma AG (Germany) II-77
Bracco Group (Italy) II-77
Covidien (USA) II-78
Daiichi Sankyo Company Limited (Japan) II-78
Eisai Co Ltd. (Japan) II-79
EUSA Pharma, Inc. (UK) II-79
GE Healthcare (UK) II-79
Guerbet Group (France) II-80
Lantheus Medical Imaging (USA) II-80

13. GLOBAL MARKET PERSPECTIVE II-81
Table 6: World Recent Past, Current & Future Analysis for
Imaging Agents by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-81

Table 7: World Historic Review for Imaging Agents by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-82

Table 8: World 15-Year Perspective for Imaging Agents by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-83

Table 9: World Recent Past, Current & Future Analysis for
Contrast Media by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-84

Table 10: World Historic Review for Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia- Pacific
(excluding Japan), Middle East and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-85

Table 11: World 15-Year Perspective for Contrast Media by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-86

Table 12: World Recent Past, Current & Future Analysis for
Contrast Media by Product Segments - X-Ray, MRI and Ultrasound
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-87

Table 13: World Historic Review for Contrast Media by Product
Segments - X-Ray, MRI and Ultrasound Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) II-88

Table 14: World 15-Year Perspective for Contrast Media by
Product Segments - Percentage Breakdown of Dollar Sales for
X-Ray, MRI and Ultrasound Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) II-89

Table 15: World Recent Past, Current & Future Analysis for
X-Ray Contrast Media by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-90

Table 16: World Historic Review for X-ray Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-91

Table 17: World 15-Year Perspective for X-Ray Contrast Media
by Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-92

Table 18: World Recent Past, Current & Future Analysis for MRI
Contrast Media by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Middle East and Latin
America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-93

Table 19: World Historic Review for MRI Contrast Media by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-94

Table 20: World 15-Year Perspective for MRI Contrast Media by
Geographic Region- Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-95

Table 21: World Recent Past, Current & Future Analysis for
Ultrasound Contrast Media by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Middle East and
Latin America Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-96

Table 22: World Historic Review for Ultrasound Contrast Media
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin American Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-97

Table 23: World 15-Year Perspective for Ultrasound Contrast
Media by Geographic Region- Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Middle East and Latin America Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-98

Table 24: World Recent Past, Current & Future Analysis for
Diagnostic Radiopharmaceuticals by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle
East and Latin America Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) II-99

Table 25: World Historic Review for Diagnostic
Radiopharmaceuticals by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Middle East and
Latin American Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) II-100

Table 26: World 15-Year Perspective for Diagnostic
Radiopharmaceuticals by Geographic Region- Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-101


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Imaging Centers Feel the Heat During Recession III-1
Growth Stimulants III-2
Dynamics of Pricing III-2
Diagnostic Radiopharmaceuticals III-3
Market Scenario III-3
Availability of Isotopes: A Tough Challenge III-3
Radiopharmaceuticals to Drive Growth III-3
Competitive Analysis - Imaging Market III-4
Reimbursement Issues III-4
Medicare III-4
Magnetic Resonance Imaging III-5
Regulatory Environment III-6
Provisions Regarding Off-Label Usage of Contrast Media III-7
Contrast Media III-7
X-ray Contrast Media III-7
MRI Contrast Media III-7
Market Scenario III-7
Managed Care Vs MRI Technology Diffusion III-8
Ultrasound Contrast Media III-8
B.Market Analytics III-9
Table 27: US Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-9

Table 28: US Historic Review for Imaging Agents by Product
Segment - Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-10

Table 29: US 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-11

2. CANADA III-12
A.Market Analysis III-12
Outlook III-12
Diagnostic Equipment Market III-12
LOCM Products Approved in Canada III-12
B.Market Analytics III-13
Table 30: Canadian Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment- Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-13

Table 31: Canadian Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-14

Table 32: Canadian 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-15

3. JAPAN III-16
A.Market Analysis III-16
Outlook III-16
Reimbursement Issues III-16
B.Market Analytics III-17
Table 33: Japanese Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-17

Table 34: Japanese Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-18

Table 35: Japanese 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-19

4. EUROPE III-20
A.Market Analysis III-20
Outlook III-20
Trends III-20
Reimbursement III-20
Outsourcing of Imaging Diagnostics III-21
Distribution Structure III-21
Direct Sales III-21
License Agreements III-21
Distribution Agreements III-21
A Price Sensitive Market III-22
Macro Environment III-22
Germany III-22
France III-22
Spain & Italy III-22
Scandinavia III-23
B.Market Analytics III-24
Table 36: European Recent Past, Current & Future Analysis
for Imaging Agents by Geographic Region - France, Germany,
UK, Italy, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2009 through 2017 (includes corresponding Graph/Chart) III-24

Table 37: European Historic Review for Imaging Agents by
Geographic Region - France, Germany, UK, Italy, Spain,
Russia and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-25

Table 38: European 15-Year Perspective for Imaging Agents by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, UK, Italy, Spain, Russia and Rest of Europe
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) III-26

Table 39: European Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-27

Table 40: European Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-28

Table 41: European 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-29

4a. FRANCE III-30
A.Market Analysis III-30
Growth Stimulants III-30
B.Market Analytics III-30
Table 42: French Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-30

Table 43: French Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-31

Table 44: French 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) & Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-32

4b. GERMANY III-33
Market Analytics III-33
Table 45: German Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-33

Table 46: German Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-34

Table 47: German 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-35

4c. ITALY III-36
Market Analytics III-36
Table 48: Italian Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-36

Table 49: Italian Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-37

Table 50: Italian 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-38

4d. THE UNITED KINGDOM III-39
Market Analytics III-39
Table 51: UK Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-39

Table 52: UK Historic Review for Imaging Agents by Product
Segment - Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-40

Table 53: UK 15-Year Perspective for Imaging Agents by
Product Segment Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-41

4e. SPAIN III-42
Market Analytics III-42
Table 54: Spanish Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment - Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-42

Table 55: Spanish Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-43

Table 56: Spanish 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-44

4f. RUSSIA III-45
Market Analytics III-45
Table 57: Russian Recent Past, Current & Future Analysis for
Imaging Agents by Product Segment -Contrast Media (X-ray,
MRI and Ultrasound) and Diagnostic Radiopharmaceuticals
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) III-45

Table 58: Russian Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-46

Table 59: Russian 15-Year Perspective for Imaging Agents by
Product Segment - Percentage Breakdown of Dollar Sales for
Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets for Years 2003, 2011 & 2017
(includes corresponding Graph/Chart) III-47

4g. REST OF EUROPE III-48
Market Analytics III-48
Table 60: Rest of Europe Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment - Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-48

Table 61: Rest of Europe Historic Review for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-49

Table 62: Rest of Europe 15-Year Perspective for Imaging
Agents by Product Segment - Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-50

5. ASIA-PACIFIC III-51
A.Market Analysis III-51
MRI Market in Asia III-51
ANSTO: Leading the Radiopharmaceuticals Market III-51
India - A High Potential Market III-51
B.Market Analytics III-52
Table 63: Asia-Pacific Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment - Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-52

Table 64: Asia-Pacific Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-53

Table 65: Asia-Pacific 15-Year Perspective for Imaging
Agents by Product Segment - Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-54

6. THE MIDDLE EAST III-55
Market Analytics III-55
Table 66: Middle East Recent Past, Current & Future Analysis
for Imaging Agents by Product Segment - Contrast Media
(X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-55

Table 67: Middle East Historic Review for Imaging Agents by
Product Segment - Contrast Media (X-ray, MRI and Ultrasound)
and Diagnostic Radiopharmaceuticals Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-56

Table 68: Middle East 15-Year Perspective for Imaging Agents
by Product Segment - Percentage Breakdown of Dollar Sales
for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-57

7. LATIN AMERICA III-58
A.Market Analysis III-58
Private Sector Boosts Healthcare Segment III-58
B.Market Analytics III-58
Table 69: Latin American Recent Past, Current & Future
Analysis for Imaging Agents by Product Segment - Contrast
Media (X-ray, MRI and Ultrasound) and Diagnostic
Radiopharmaceuticals Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-58

Table 70: Latin American Historic Review for Imaging Agents
by Product Segment - Contrast Media (X-ray, MRI and
Ultrasound) and Diagnostic Radiopharmaceuticals
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-59

Table 71: Latin American 15-Year Perspective for Imaging
Agents by Product Segment - Percentage Breakdown of Dollar
Sales for Contrast Media (X-ray, MRI and Ultrasound) and
Diagnostic Radiopharmaceuticals Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) III-60


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 55 (including Divisions/Subsidiaries - 68)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 36
Canada 3
Japan 5
Europe 18
France 1
Germany 6
The United Kingdom 3
Italy 2
Rest of Europe 6
Asia-Pacific (Excluding Japan) 5
Africa 1
------------------------------------------